血清Tg值受干扰时监测TGAb水平变化对分化型甲状腺癌患者的临床意义
The Clinical Significance of Monitoring the Changes of TGAb Level in Patients with Differentiated Thyroid Cancer When Serum Tg Value Is False Negative
DOI: 10.12677/ACM.2022.126758, PDF,  被引量   
作者: 袁明雪, 余志威, 张 瑾:青海大学,青海 西宁;赵海宁:青海大学附属医院乳腺甲状腺外科,青海 西宁
关键词: 甲状腺球蛋白甲状腺球蛋白抗体水平变化分化型甲状腺癌综述Thyroglobulin Changes of Thyroglobulin Antibody Level Differentiated Thyroid Carcinoma Review
摘要: 甲状腺球蛋白(thyroglobulin, Tg),是分化型甲状腺癌(differentiated thyroid carcinoma, DTC)患者治疗后进行随访的血清肿瘤标志物。但血清Tg值测定时会存在一定的干扰因素,Tg实验检测方法、甲状腺球蛋白抗体(thyroglobulin antibody, TgAb)等,都会导致假阴性/无法检测Tg值,则削弱了Tg对疾病的评估作用进而掩盖疾病。TGAb与DTC术后复发/转移有一定关联性,从而用于预测预后,但目前尚无定论,且存在争议。血清TgAb水平变化能否代替Tg作为肿瘤预测标记物已成为学者的研究热点,通过大量研究并得出普遍认可的结果,即TgAb可以作为新的肿瘤标志物用于DTC术后的随访监测。故研究假阴性/无法检测Tg值的DTC患者中血清TGAb水平变化,在Tg值受干扰时分析TGAb水平变化,对DTC疾病的价值意义进行综述。进而指导DTC患者术后随访及个体诊疗,从而为DTC患者术后的防治策略提供科学依据。
Abstract: Thyroglobulin (Tg), is a serum tumor marker in patients with differentiated thyroid cancer (DTC) followed up after treatment. However, there are some interference factors in the determination of serum Tg. Both the Tg experimental detection methods and thyroglobulin antibody (TgAb) lead to false negative/no Tg detection, which weakens the role of Tg in the evaluation of diseases and thus covers up diseases. TGAb has a certain correlation with postoperative recurrence/metastasis of DTC, so it can be used to predict prognosis, but there is still no conclusion and controversy. When serum TgAb monitoring is positive, whether Tg can replace Tg as a marker for tumor prediction has be-come a hot topic of scholars’ research. Through a large number of studies, it has been generally recognized that TgAb can be used as a new tumor marker for follow-up monitoring after DTC. Therefore, the change of serum TGAb level in DTC patients with false negative/undetectable Tg value was studied, and the value of the change in serum TGAb level in DTC diseases with inaccurate Tg value was analyzed and summarized, to guide the postoperative follow-up and individual diag-nosis and treatment of DTC patients, so as to provide a scientific basis for the postoperative preven-tion and treatment strategies of DTC patients.
文章引用:袁明雪, 赵海宁, 余志威, 张瑾. 血清Tg值受干扰时监测TGAb水平变化对分化型甲状腺癌患者的临床意义[J]. 临床医学进展, 2022, 12(6): 5236-5244. https://doi.org/10.12677/ACM.2022.126758

参考文献

[1] 程少浩, 苏艳军, 程若川. TgAb干扰血清Tg检测的相关因素研究进展[J]. 山东医药, 2021, 61(11): 85-88.
[2] 彭朝艳, 廖延, 王睿, 等. 甲状腺球蛋白测定在甲状腺癌中的应用及研究进展[J]. 标记免疫分析与临床, 2021, 28(7): 1253-1257.
[3] Latrofa, F., Ricci, D., Bottai, S., et al. (2018) Effect of Thyroglobulin Autoantibodies on the Metabolic Clearance of Serum Thyroglobulin. Thyroid, 28, 288-294. [Google Scholar] [CrossRef] [PubMed]
[4] Weigle, W.O. and High, G.J. (1967) The Behavior of Autologous Thyroglobulin in the Circulation of Rabbits Immunized with Either Heterologous or Altered Homologous Thyroglobulin. The Journal of Immunology, 98, 1105-1114.
[5] Algeciras-Schimnich, A. (2018) Thyroglobulin Measurement in the Management of Patients with Differentiated Thyroid Cancer. Critical Reviews in Clinical Laboratory Sciences, 55, 205-218. [Google Scholar] [CrossRef] [PubMed]
[6] Spencer, C. and Fatemi, S. (2013) Thyroglobulin Antibody (TgAb) Methods—Strengths, Pitfalls and Clinical Utility for Monitoring TgAb-Positive Patients with Differentiated Thyroid Cancer. Best Practice & Research Clinical Endocrinology & Metabolism, 27, 701-712. [Google Scholar] [CrossRef] [PubMed]
[7] Spencer, C., LoPresti, J. and Fatemi, S. (2014) How Sensitive (Second-Generation) Thyroglobulin Measurement Is Changing Paradigms for Monitoring Patients with Differentiated Thyroid Cancer, in the Absence or Presence of Thyroglobulin Autoantibodies. Current Opinion in Endocrinology, Dia-betes and Obesity, 21, 394-404. [Google Scholar] [CrossRef
[8] Demers, L.M. and Spencer, C.A. (2003) Laboratory Medi-cine Practice Guidelines: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease. Clinical Endocri-nology, 58, 138-140. [Google Scholar] [CrossRef] [PubMed]
[9] Spencer, C.A., Bergoglio, L.M., Kazarosyan, M., et al. (2005) Clinical Impact of Thyroglobulin (Tg) and Tg Autoantibody Method Differences on the Management of Patients with Differentiated Thyroid Carcinomas. The Journal of Clinical Endocrinology & Metabolism, 90, 5566-5575. [Google Scholar] [CrossRef] [PubMed]
[10] Netzel, B.C., Grebe, S.K., Carranza, L.B., et al. (2015) Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results with Clinical Outcomes. The Journal of Clinical Endocrinology & Metabolism, 100, E1074-E1083. [Google Scholar] [CrossRef] [PubMed]
[11] Azmat, U., Porter, K., Senter, L., et al. (2017) Thyroglobulin Liquid Chromatography-Tandem Mass Spectrometry Has a Low Sen-sitivity for Detecting Structural Disease in Patients with Antithyroglobulin Antibodies. Thyroid, 27, 74-80. [Google Scholar] [CrossRef] [PubMed]
[12] Clark, P.M. (2009) Laboratory Services for Thyroglobulin and Impli-cations for Monitoring of Differentiated Thyroid Cancer. Journal of Clinical Pathology, 62, 402-406. [Google Scholar] [CrossRef] [PubMed]
[13] Cunha, N., Rodrigues, F., Curado, F., et al. (2007) Thyroglobulin Detection in Fine-Needle Aspirates of Cervical Lymph Nodes: A Technique for the Diagnosis of Metastatic Differentiat-ed Thyroid Cancer. European Journal of Endocrinology, 157, 101-107. [Google Scholar] [CrossRef
[14] van der Laken, C.J., Voskuyl, A.E., Roos, J.C., et al. (2007) Imaging and Serum Analysis of Immune Complex Formation of Radiolabelled Infliximab and Anti-Infliximab in Responders and Non-Responders to Therapy for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 66, 253-256. [Google Scholar] [CrossRef] [PubMed]
[15] Spencer, C.A. and Lopresti, J.S. (2008) Measuring Thyroglobulin and Thyroglobulin Autoantibody in Patients with Differentiated Thyroid Cancer. Nature Clinical Practice. Endocrinology & Metabolism, 4, 223-233. [Google Scholar] [CrossRef] [PubMed]
[16] Spencer, C.A. (2011) Clinical Review: Clinical Utility of Thyroglobu-lin Antibody (TgAb) Measurements for Patients with Differentiated Thyroid Cancers (DTC). The Journal of Clinical Endocrinology and Metabolism, 96, 3615-3627. [Google Scholar] [CrossRef] [PubMed]
[17] Cooper, D.S., Doherty, G.M., Haugen, B.R., et al. (2009) Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 19, 1167-1214. [Google Scholar] [CrossRef] [PubMed]
[18] Kim, E.S., Lim, D.J., Baek, K.H., et al. (2010) Thyroglobulin Anti-body Is Associated with Increased Cancer Risk in Thyroid Nodules. Thyroid, 20, 885-891. [Google Scholar] [CrossRef] [PubMed]
[19] Vasileiadis, I., Boutzios, G., Charitoudis, G., et al. (2014) Thyroglobu-lin Antibodies Could Be a Potential Predictive Marker for Papillary Thyroid Carcinoma. Annals of Surgical Oncology, 21, 2725-2732. [Google Scholar] [CrossRef] [PubMed]
[20] Hosseini, S., Payne, R.J., Zawawi, F., et al. (2016) Can Preoper-ative Thyroglobulin Antibody Levels be Used as a Marker for Well Differentiated Thyroid Cancer? Journal of Otolaryn-gology—Head & Neck Surgery, 45, Article No. 31. [Google Scholar] [CrossRef] [PubMed]
[21] Kim, W.G., Yoon, J.H., Kim, W.B., et al. (2008) Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin-Negative Patients with Differentiated Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism, 93, 4683-4689. [Google Scholar] [CrossRef] [PubMed]
[22] Feldt-Rasmussen, U., Blichert-Toft, M., Christiansen, C., et al. (1982) Serum Thyroglobulin and Its Autoantibody Following Subtotal Thyroid Resection of Graves’ Disease. European Journal of Clinical Investigation, 12, 203-208. [Google Scholar] [CrossRef] [PubMed]
[23] Chiovato, L., Latrofa, F., Braverman, L.E., et al. (2003) Disappearance of Humoral Thyroid Autoimmunity after Complete Removal of Thyroid Antigens. Annals of Internal Medicine, 139, 346-351. [Google Scholar] [CrossRef
[24] Gorges, R., Maniecki, M., Jentzen, W., et al. (2005) Development and Clinical Impact of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Car-cinoma during the First 3 Years after Thyroidectomy. European Journal of Endocrinology, 153, 49-55. [Google Scholar] [CrossRef] [PubMed]
[25] Matrone, A., Latrofa, F., Torregrossa, L., et al. (2018) Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy without 131I Ablation. Thyroid, 28, 871-879. [Google Scholar] [CrossRef] [PubMed]
[26] Durante, C., Tognini, S., Montesano, T., et al. (2014) Clinical Aggres-siveness and Long-Term Outcome in Patients with Papillary Thyroid Cancer and Circulating Anti-Thyroglobulin Autoan-tibodies. Thyroid, 24, 1139-1145. [Google Scholar] [CrossRef] [PubMed]
[27] 张娜, 林岩松, 梁军. 甲状腺球蛋白抗体测定在分化型甲状腺癌131I治疗中的临床意义[J]. 中国癌症杂志, 2019, 29(6): 452-456.
[28] Ozkan, E., Soydal, C., Araz, M., et al. (2012) The Additive Clinical Value of 18F-FDG PET/CT in Defining the Recurrence of Disease in Patients with Differentiated Thyroid Cancer Who Have Isolated Increased Antithyroglobulin Antibody Levels. Clinical Nuclear Medicine, 37, 755-758. [Google Scholar] [CrossRef
[29] Slifka, M.K., Antia, R., Whitmire, J.K., et al. (1998) Humoral Immunity Due to Long-Lived Plasma Cells. Immunity, 8, 363-372. [Google Scholar] [CrossRef
[30] Chung, J.K., Park, Y.J., Kim, T.Y., et al. (2002) Clinical Significance of Elevated Level of Serum Antithyroglobulin Antibody in Patients with Differentiated Thyroid Cancer after Thyroid Ablation. Clinical Endocrinology, 57, 215-221. [Google Scholar] [CrossRef] [PubMed]
[31] Nixon, I.J., Whitcher, M.M., Palmer, F.L., et al. (2012) The Impact of Distant Metastases at Presentation on Prognosis in Patients with Differentiated Carcinoma of the Thyroid Gland. Thyroid, 22, 884-889. [Google Scholar] [CrossRef] [PubMed]
[32] Spencer, C. (2013) Commentary on: Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement. Thyroid, 23, 1190-1192. [Google Scholar] [CrossRef] [PubMed]
[33] Trimboli, P., Zilioli, V., Imperiali, M., et al. (2017) Thy-roglobulin Autoantibodies before Radioiodine Ablation Predict Differentiated Thyroid Cancer Outcome. Clinical Chem-istry and Laboratory Medicine, 55, 1995-2001. [Google Scholar] [CrossRef] [PubMed]
[34] Seo, J.H., Lee, S.W., Ahn, B.C., et al. (2010) Recurrence Detection in Differentiated Thyroid Cancer Patients with Elevated Serum Level of Antithyroglobulin Antibody: Special Emphasis on Using (18)F-FDG PET/CT. Clinical Endocrinology, 72, 558-563. [Google Scholar] [CrossRef] [PubMed]
[35] Chai, H., Zhu, Z.J., Chen, Z.Q., et al. (2016) Diagnostic Value of Tg and TgAb for Metastasis Following Ablation in Patients with Differentiated Thyroid Carcinoma Coexistent with Hashimoto Thyroiditis. Endocrine Research, 41, 218-222. [Google Scholar] [CrossRef] [PubMed]
[36] Grani, G., Calvanese, A., Carbotta, G., et al. (2015) Thyroid Autoimmunity and Risk of Malignancy in Thyroid Nodules Submitted to Fine-Needle Aspiration Cytology. Head & Neck, 37, 260-264. [Google Scholar] [CrossRef] [PubMed]
[37] Gianoukakis, A.G. (2015) Thyroglobulin Antibody Status and Differentiated Thyroid Cancer: What Does It Mean for Prognosis and Surveillance? Current Opinion in On-cology, 27, 26-32. [Google Scholar] [CrossRef
[38] Haugen, B.R., Alexander, E.K., Bible, K.C., et al. (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thy-roid Cancer. Thyroid, 26, 1-133. [Google Scholar] [CrossRef] [PubMed]
[39] Pacini, F., Mariotti, S., Formica, N., et al. (1988) Thyroid Autoanti-bodies in Thyroid Cancer: Incidence and Relationship with Tumour Outcome. Acta Endocrinologica, 119, 373-380. [Google Scholar] [CrossRef] [PubMed]
[40] Li, C., Yu, W., Fan, J., et al. (2016) Thyroid Functional Parameters and Correlative Autoantibodies as Prognostic Factors for Differentiated Thyroid Cancers. Oncotarget, 7, 49930-49938. [Google Scholar] [CrossRef] [PubMed]
[41] Alexandru, D., Glantz, M.J., Kim, L., et al. (2011) Pulmonary Metastases in Patients with Recurrent, Treatment-Resistant Meningioma: Prognosis and Identification by 111Indium-Octreotide Imaging. Cancer, 117, 4506-4511. [Google Scholar] [CrossRef] [PubMed]
[42] Lee, Z., Eslick, G.D. and Edirimanne, S. (2020) Investigating Antithy-roglobulin Antibody as a Prognostic Marker for Differentiated Thyroid Cancer: A Meta-Analysis and Systematic Review. Thyroid, 30, 1601-1612. [Google Scholar] [CrossRef] [PubMed]